Ebola Bundibugyo Outbreak in DRC, Uganda: Gavi Responds to Global Emergency

Gavi, the Vaccine Alliance, has issued a statement confirming its close monitoring of a severe Ebola disease outbreak caused by the Bundibugyo virus (BVD) currently affecting the Democratic Republic of the Congo (DRC) and Uganda. This critical health crisis prompted the World Health Organization (WHO) Director-General to declare a Public Health Emergency of International Concern (PHEIC) on May 17, 2026, followed by the Africa Centres for Disease Control and Prevention (Africa CDC) declaring a Public Health Emergency of Continental Security (PHECS) on May 18, 2026. The situation is rapidly evolving, with more than 500 suspected cases and over 130 deaths reported in the DRC, predominantly in Ituri and North Kivu provinces. Confirmed cases have also emerged in Kampala, Uganda, indicating cross-border spread. As of May 21, 2026, official reports from the DRC and Uganda Ministries of Health indicated 575 suspected cases, 51 confirmed cases, and 148 suspected deaths, including two confirmed cases and one death in Uganda linked to travel from the DRC. A primary concern for global health security is the absence of licensed vaccines or therapeutics specifically effective against the Bundibugyo virus. This makes the current outbreak particularly challenging, especially given its transmission amidst mobile, conflict-affected, and hard-to-reach populations in the region. Experts, including Dr. Gabriel Nsakala, a public health professor involved in past Ebola responses, highlight that while Congo has extensive experience managing Ebola outbreaks, the unusual Bundibugyo strain complicates response efforts. In response to this grave situation, Gavi, as the global vaccine alliance, is actively coordinating with key partners. These include the Coalition for Epidemic Preparedness Innovations (CEPI), WHO, Africa CDC, UNICEF, the World Bank, and the Pandemic Fund, alongside the affected countries, to assess needs and determine the most effective ways to support outbreak response efforts and safeguard essential public health services like routine immunization. It is important to note that Gavi currently funds the global stockpile of Ebola vaccines, which consists of Ervebo, a vaccine licensed for use against the Zaire ebolavirus species. This stockpile, maintained at 500,000 doses, is accessible worldwide, with lower-income countries eligible for Gavi support receiving doses for free, along with financing for outbreak response vaccination activities. The Ervebo vaccine has proven highly effective against the Zaire strain, with studies showing an 84% efficacy during the 2018–2020 Kivu Ebola epidemic. It has been deployed successfully in previous Zaire Ebola outbreaks, significantly reducing cases and deaths. However, due to the extremely limited evidence on cross-protection against non-Zaire species, any decision to use the Zaire-specific vaccine in the current Bundibugyo outbreak would require further assessments and strict adherence to WHO guidance. Such a decision would also necessitate the explicit informed consent and understanding of affected communities regarding the unknown benefits of the vaccine against BVD. Gavi is also evaluating how its First Response Fund (FRF) could be leveraged to provide targeted deployment of resources. The FRF, a mechanism established with learnings from the COVID-19 pandemic, is designed to facilitate rapid access to vaccines outside Gavi's core portfolio during public health emergencies and has a total of US$500 million available through 2030. Up to US$50 million can be used at the discretion of the Gavi CEO for rapid response, with larger amounts requiring Gavi Board approval. The current outbreak underscores the persistent challenges in global health security, particularly in regions like the DRC, which has experienced numerous Ebola outbreaks since 1976. The affected areas are often characterized by conflict, population displacement, and porous borders, which exacerbate the risk of disease spread. The international community, including Gavi, is committed to supporting a country-led, highly coordinated, and evidence-based response to contain this deeply concerning Bundibugyo virus disease outbreak. For an Indian audience, this news highlights the ongoing global health threats and the importance of international cooperation in combating infectious diseases, even if directly affecting distant regions. The potential for global spread of such outbreaks emphasizes the interconnectedness of health security worldwide. The rapid response and resource mobilization efforts by organizations like Gavi and WHO are crucial in preventing such outbreaks from escalating into wider pandemics, which could indirectly impact India through travel restrictions or economic disruptions. Previous Ebola outbreaks in DRC and Uganda, such as the 2018-2020 Kivu epidemic (Zaire strain), which was the second-largest Ebola outbreak globally, saw extensive vaccination campaigns and international support, ultimately leading to its containment. Uganda itself has a history of multiple Ebola outbreaks, successfully containing them with effective strategies. This experience, coupled with coordinated international efforts, is vital in addressing the current Bundibugyo challenge, despite the lack of a specific vaccine.

Frequently Asked Questions

Read Full Story on Quick Digest